PTC Therapeutics (PTCT) raised its full-year 2026 revenue guidance to $850 million to $950 million at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, citing strong performance from its flagship product Sephience. The company’s cash balance stood at $2.2 billion as of the end of Q2 2026, supporting its financial transition toward profitability. With a market capitalization of $5.45 billion, PTC remains well-positioned amid a competitive rare-disease therapeutics landscape, where its revenue had declined 43% over the trailing twelve months to $1.01 billion—a shift driven by the launch of Sephience and strategic investments in its pipeline.
PTC Therapeutics Raises 2026 Revenue Guidance Amid Sephience Success
Sephience’s rapid adoption and clinical milestones bolster PTC’s outlook, with cash flow breakeven expected in 2026 as the company expands its rare-disease pipeline.
PA
Priya Anand · Equities & Earnings Desk · 16 Sept 2026 · 07:54 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
